BI-3812
CAS No. 2166387-64-8
BI-3812( BI3812 | BI 3812 )
Catalog No. M13458 CAS No. 2166387-64-8
A highly potent and efficacious BCL6 inhibitor that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 149 | Get Quote |
|
| 5MG | 237 | Get Quote |
|
| 10MG | 402 | Get Quote |
|
| 25MG | 665 | Get Quote |
|
| 50MG | 888 | Get Quote |
|
| 100MG | 1251 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBI-3812
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent and efficacious BCL6 inhibitor that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM.
-
DescriptionA highly potent and efficacious BCL6 inhibitor that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM; inhibits the BCL6/Co-repressor complex formation with IC50 of 40 nM in vitro.
-
In Vitro——
-
In Vivo——
-
SynonymsBI3812 | BI 3812
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number2166387-64-8
-
Formula Weight558.036
-
Molecular FormulaC26H32ClN7O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : 20.83 mg/mL 37.33 mM; H2O : < 0.1 mg/mL
-
SMILESO=C(C1CCN(C2=NC=C(Cl)C(NC3=CC4=C(N(C)C(C(OCC(NC)=O)=C4)=O)C(OC)=C3)=N2)CC1)N(C)C
-
Chemical Name1-(5-chloro-4-((8-methoxy-1-methyl-3-(2-(methylamino)-2-oxoethoxy)-2-oxo-1,2-dihydroquinolin-6-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kerres N, et al. Cell Rep. 2017 Sep 19;20(12):2860-2875.
molnova catalog
related products
-
Mcl1-IN-2
Mcl1-IN-2 is an Mcl-1 inhibitor without a reported IC50 value.
-
BDA-366
A potent, selective Bcl2 BH4 domain antagonist with Ki of 3.3 nM; shows no affinity for other Bcl2 family members, including Bcl-XL, Mcl-1, or Bfl-1/A1.
-
Paederosidic acid
Paederosidic acid has significant anti-tumor anticonvulsant and sedative effects. Paederosidic acid increases brain gamma-aminobutyric acid and decreases glutamic acid in the brain and it up-regulates expressions of GAD 65 may be a promising future therapeutic agent for treatment of epilepsy.
Cart
sales@molnova.com